Full Press Release Details
("OKYO" or "the Company")
Allotment of Ordinary
Shares and Total Voting Rights
OKYO Pharma Limited (LSE:OKYO; NASDAQ: OKYO) (the
"Company") today announces that pursuant to an agreement dated 1 February 2023 between the Company and TraDigital Marketing
Group, LLC ("TraDigital Marketing"), in consideration for the provision of various consulting services by TraDigital
Marketing (the "Services Agreement"), the Company has agreed to allot and issue 2,177,500 ordinary shares of no par value
in the capital of the Company (the "Stock Fee Shares").
Applications have been made to the Financial Conduct
Authority (the "FCA") for the Stock Fee Shares to be admitted to listing on the standard segment of the Official List
maintained by the FCA and to trading on the main market for listed securities of London Stock Exchange plc. It is expected that admission
will occur on or around 8.00 a.m. on 16 February 2023.
Following the issue of the Stock Fee Shares,
the Company's issued share capital will consist of 1,417,217,968 ordinary shares in the capital of the Company, with voting rights.
This figure may be used by shareholders in the Company as the denominator for the calculation by which they will determine if they are
required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure
Guidance and Transparency Rules. The Company does not hold any Ordinary Shares in treasury.
| OKYO Pharma Limited | Gary S. Jacob Chief Executive Officer | +44 (0)20 7495 2379 | ||
| Optiva Securities Limited Broker | Robert Emmet | +44 (0)20 3981 4173 |
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO)
is a life sciences company admitted to listing on NASDAQ and on the standard segment of the Official List of the UK Financial Conduct
Authority and to trading on the main market for listed securities of London Stock Exchange plc. OKYO is focusing on the discovery and
development of novel molecules to treat inflammatory dry eye diseases and chronic pain. For further information, please visit the Company's
website at www.okyopharma.com
OK-101 is a lipid conjugated chemerin peptide
antagonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory
response. OK-101 was developed using a membrane-anchored-peptide (MAP) technology to produce a novel long-acting drug candidate for treating
dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and
corneal neuropathic pain; and is designed to combat washout through the inclusion of the lipid anchor' contained in the candidate drug
molecule to enhance the residence time of OK-101 within the ocular environment.
About Dry Eye Disease
Dry eye disease is a multifactorial disease that
results in ocular discomfort and tear film instability that can lead to ocular surface damage. It is often a chronic problem, particularly
in older adults, and is expected to become even more prevalent with the aging population and increased use of digital screens such as
computers and smart phones. Despite new product approvals, dry eye disease remains a significant unmet medical need and is one of the
leading causes for patient visits to eye care specialists. Novel therapies that improve the signs and symptoms of dry eye disease will
be beneficial to dry eye patients.